Eini Nikander
Helsinki University Central Hospital
8 Papers
57 Citations
Eini Nikander is an academic researcher from Helsinki University Central Hospital. The author has contributed to research in topics: Phytoestrogens & Reverse cholesterol transport. The author has an hindex of 8, co-authored 8 publications. Previous affiliations of Eini Nikander include Jorvi Hospital.
Chat about Author
Papers
A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients.
Eini Nikander,Annamari Kilkkinen,Merja Metsä-Heikkilä,Herman Adlercreutz,Pirjo Pietinen,Aila Tiitinen,Olavi Ylikorkala +6 more
TL;DR: Pure isoflavonoids did not alleviate subjective menopausal symptoms in breast cancer patients and the quality of life parameters (working capacity, mood changes) were unaffected by phytoestrogen.
156
Evidence of a lack of effect of a phytoestrogen regimen on the levels of C-reactive protein, E-selectin, and nitrate in postmenopausal women.
TL;DR: Data are suggested, suggesting neutral effects of phytoestrogens on CRP, E-selectin, and nitric oxide, fail to support a vasoprotective role of phYtoestrogen in postmenopausal women.
80
Effects of isolated isoflavonoids on lipids, lipoproteins, insulin sensitivity, and ghrelin in postmenopausal women.
Eini Nikander,Eini Nikander,Aila Tiitinen,Kalevi Laitinen,Matti J. Tikkanen,Olavi Ylikorkala +5 more
TL;DR: No effects of isolated isoflavonoids on lipids, lipoproteins, or insulin sensitivity in postmenopausal women, implying no vascular benefit, are found, and Isoflavonoids may reduce ghrelin levels and thus hunger and weight.
Effects of Phytoestrogens on Bone Turnover in Postmenopausal Women with a History of Breast Cancer
TL;DR: Bone resorption was reduced during phytoestrogen use, as reflected in falls in the urinary output of Pyr and Dpyr and N-terminal cross-linked telopeptide of type I collagen showed a trend toward significance.
Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
TL;DR: Tamoxifen (20 mg) and toremifene (40 mg) have similar bone-sparing efficacy that in lumbar spine extends up to 1 year after the cessation of these regimens, but this effect is not seen in lumberar spine BMD in those postmenopausal women who discontinue HRT at the time of breast cancer diagnosis.
22